DRKS00033130招募中不适用
Predicting the response to therapy of inflammatory bowel disease with infrared spectroscopy - PROPHECY
niversitätsklinikum Erlangen0 个研究点目标入组 1,500 人开始时间: 2023年12月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •established diagnosis of ulcerative colitis or Crohn's disease
- •- diagnostic ileocolonoscopy with biopsies and subsequent initiation of a novel anti-inflammatory therapy
排除标准
- •- drugs, concomitant diseases or conditions that preclude the assessment of clinical response/remission
研究者
相似试验
未知
不适用
Prediction of the effect of treatments for inflammatory bowel disease patients by using colon ultra sonography imagingInflammatory bowel disease(IBD)JPRN-UMIN000002250Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine260
招募中
不适用
Predicting response to biologics in inflammatory bowel diseaseInflammatory bowel diseaseOral and Gastrointestinal - Inflammatory bowel diseaseACTRN12613001292763niversity of Otago Christchurch160
招募中
不适用
Prediction of therapy response and treatment outcomes in early course of schizophrenia.Subproject D1_AP2 of the research network ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments)DSM IV-TR:295.10-30, 295.90: Schizophrenia High Risc State of transmission to psychosisDRKS00010936Klinik und Poliklinik für Psychiatrie und Psychotherapie,LVR-Klinikum Düsseldorf / Kliniken der Heinrich Heine Universität Düsseldorf600
已完成
不适用
Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).Rheumatoid arthritisJPRN-UMIN000020134Jichi Medical University56
已完成
不适用
Biomonitoring of inflammation, therapy response and regeneration in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis during therapy with Certolizumab PegolM06.99M07.00M45.00DRKS00012509Charité Campus Charité Mitte137